Scholarlink

Purpose <p>To evaluate the diagnostic utility of salivary cortisol (CS) as a non-invasive screening and monitoring tool for adrenal insufficiency (AI), and to assess its capacity to reflect cortisol exposure in patients receiving hydrocortisone (HC) replacement therapy.</p> Methods <p>This prospective study included adult patients with clinical suspicion of primary or secondary AI who underwent ACTH stimulation testing (ACTH-t) and provided ambulatory CS samples at five time points (08:00, 13:00, 18:00, 24:00, and 08:00 the following day). CS was quantified via electrochemiluminescence immunoassay. Diagnostic performance, optimal thresholds, and correlations with morning serum cortisol (CB) and HC dosing were analyzed.</p> Results <p>Out of 60 patients included, 11 (18.3%) were diagnosed with AI. CS8 had a higher AUC than CB (0.804 vs. 0.739), -non-significant difference between AUC-. A CS8 threshold &lt; 0.0975&#xa0;µg/dL yielded 100% sensitivity and 75% positive predictive value, while &gt; 0.708&#xa0;µg/dL achieved 100% negative predictive value. Afternoon and evening CS levels were significantly higher in HC-treated patients, with elevated diurnal 08:00–24:00 cortisol exposure (AUC 7.82[2.57–11.14] vs. 2.73[2.19–3.79] ng·h/mL;<i>p</i> = 0.017) and a trend toward lower morning CS, suggesting overtreatment during the day and under-replacement at night 24:00–8:00 (AUC 2.06[0.67–6.13] vs. 1.6 [1.33–2.43] ng·h/mL;<i>ns)</i>.</p> Conclusions <p>CS is a reliable, non-invasive biomarker for both screening and monitoring of AI. Its ability to reflect circadian cortisol dynamics offers clinical value in assessing replacement adequacy. Salivary profiling may guide individualized HC dose titration and help avoid overtreatment. Larger studies including salivary cortisone are warranted to refine monitoring strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical utility of salivary cortisol for diagnosis and therapeutic monitoring in adrenal insufficiency

  • 期刊论文

  • 发表日期：

    2025年10月15日

查看全文
  • Pablo Fernández-Velasco,
  • Inés Anibarro Miralles,
  • Sara Rubio Lanchas,
  • Beatriz Torres Torres,
  • Ana Ortolá Buigues,
  • Emilia Gómez Hoyos,
  • Wysali Trapiello Fernández,
  • Dolores Calvo Nieves,
  • Daniel de Luis Román,
  • Gonzalo Díaz-Soto

摘要

Purpose

To evaluate the diagnostic utility of salivary cortisol (CS) as a non-invasive screening and monitoring tool for adrenal insufficiency (AI), and to assess its capacity to reflect cortisol exposure in patients receiving hydrocortisone (HC) replacement therapy.

Methods

This prospective study included adult patients with clinical suspicion of primary or secondary AI who underwent ACTH stimulation testing (ACTH-t) and provided ambulatory CS samples at five time points (08:00, 13:00, 18:00, 24:00, and 08:00 the following day). CS was quantified via electrochemiluminescence immunoassay. Diagnostic performance, optimal thresholds, and correlations with morning serum cortisol (CB) and HC dosing were analyzed.

Results

Out of 60 patients included, 11 (18.3%) were diagnosed with AI. CS8 had a higher AUC than CB (0.804 vs. 0.739), -non-significant difference between AUC-. A CS8 threshold < 0.0975 µg/dL yielded 100% sensitivity and 75% positive predictive value, while > 0.708 µg/dL achieved 100% negative predictive value. Afternoon and evening CS levels were significantly higher in HC-treated patients, with elevated diurnal 08:00–24:00 cortisol exposure (AUC 7.82[2.57–11.14] vs. 2.73[2.19–3.79] ng·h/mL;p = 0.017) and a trend toward lower morning CS, suggesting overtreatment during the day and under-replacement at night 24:00–8:00 (AUC 2.06[0.67–6.13] vs. 1.6 [1.33–2.43] ng·h/mL;ns).

Conclusions

CS is a reliable, non-invasive biomarker for both screening and monitoring of AI. Its ability to reflect circadian cortisol dynamics offers clinical value in assessing replacement adequacy. Salivary profiling may guide individualized HC dose titration and help avoid overtreatment. Larger studies including salivary cortisone are warranted to refine monitoring strategies.